This is a package of 100 capsules of Dilantin Extended Phenytoin Sodium 100 mg Capsule from Parke-Davis Div of Pfizer Inc, no longer marketed, no longer in the FDA NDC Directory; retail pharmacies pay about $1.74 per capsule (NADAC). It is the main listing for this product, which comes in 3 package sizes.
🏷️ FDA NDC (as labeled)0071-0369-24billing pads the labeler segment with a zero
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Mar 13, 2024 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy
NDC database record
One package, one record: these facts belong to NDC 0071-0369-24 alone.
Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0071 labeler · 0369 product · 24 package
Billing quantity
100 EA per package
Barcode (UPC-A, from the NDC)
3 0071036924 5
Medicaid fills, this package
2,394 prescriptions in the last four reported quarters
FDA record last changed
Mar 13, 2024
⚠️
Excluded from the active FDA NDC Directory.
The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Jun 2013. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory.
Search the FDA NDC Directory ↗
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
FDA listing statusDiscontinued by firm (certified through Jun 2013)
RouteORAL
Dosage formCAPSULE
SubstancePHENYTOIN SODIUM
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
GCN Seq No004521
GCN17700
HICL code001877
Ingredient (HICL)Phenytoin Sodium Extended
HIC1 codeH
Therapeutic class — broad (HIC1)Nervous System (Except Autonomic)
HIC2 codeH4
Therapeutic class — intermediate (HIC2)Anticonvulsants
HIC3 codeH4B
Therapeutic class — specific (HIC3)Anticonvulsants
AHFS code24:04.04.08
AHFS classClass Ib Antiarrhythmics
FDB label nameDILANTIN 100 MG CAPSULE
FDB brand nameDilantin
Legend statusF — Federal legend — prescription drug or device
Quick answers
GSN (GCN sequence number):004521
GCN:17700
HICL (First Databank):001877
AHFS class code:24:04.04.08
Why two NDCs?
The FDA registers this code as 0071-0369-24 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00071-0369-24. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
First Databank (licensed)
· refreshed Nov 19, 2026
Clinical
Label name DILANTIN 100 MG CAPSULEIngredient Phenytoin Sodium Extended
📖 What it is MedlinePlus · NLM
Phenytoin is used to control certain type of seizures, and to treat and prevent seizures that may begin during or after surgery to the brain or nervous system. Phenytoin is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.
It treats seizures. Depending on the product, that includes grand mal seizures, temporal lobe or complex partial seizures, and seizures during or after brain surgery. The injection...
No. Stopping suddenly can trigger a dangerous, prolonged seizure. If you need to reduce or stop it, your prescriber will do it gradually.
The most common are unsteadiness, eye movements, slurred speech, sleepiness and confusion. These are often dose-related, so tell your doctor if they appear. Call right away for a r...
Yes. Phenytoin interacts with many drugs, including antacids, antifungals, warfarin, blood thinners and birth control. Tell me or your doctor about everything you take, including S...
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
Price system
Per ea
Per package
Retail pharmacies payNADAC · weekly
$1.742
$174.20 / 100 capsules
Medicaid paysCMS SDUD · 12 mo
$1.67
$166.81 / 100 capsules
Medicare drug plans payPart D · quarterly
No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
▲ Up 27% over the last 23 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
100 BLISTER PACK in 1 CARTON / 1 CAPSULE in 1 BLISTER PACK
$1.66 / ea
$165.94
1976-08-27
—
Discontinued by firm
Swipe sideways for more columns →
Per ea, this pack runs about 5% above the cheapest pack (NDC 00071-0369-40, $1.66 vs $1.74 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 86% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
This is a 100-count package — 100 capsule in 1 bottle.
How does this package differ from NDC 00071-0369-40?
Both are Dilantin Extended Phenytoin Sodium 100 mg Capsule — the drug itself is identical. This page's package is the 100-count one, while NDC 00071-0369-40 is the 100 capsules package. Per-ea NADAC also differs: $1.74 here vs $1.66 for the 100 capsules pack.
What NDC number is used to bill for this package of Dilantin Extended Phenytoin Sodium 100 mg Capsule?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
Inactive ingredients, also called excipients, are components of the drug product
other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors,
or other formulation ingredients.
🧪 Avoiding an ingredient? See Phenytoin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
We could not link this NDC to a current FDA Structured Product Label. An inactive-ingredient list is therefore not available from this source.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
Manufacturer & labeler
LabelerParke-Davis Div of Pfizer Inc
Application holderVIATRIS SPECIALTY LLC
FDA applicationANDA084349 (ANDA)
Labeler code00071
Product typeHuman Prescription Drug
Portfolio14 products on file
More NDCs from Parke-Davis Div of Pfizer Inc labeler code 00071
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
2.4K
Units reimbursed last 4 qtrs
288.9K
Gross reimbursed last 4 qtrs
$481.9K
Avg / prescription
$201.30
Avg / unit
$1.6681
Latest quarter Q4 2025
51Rx
Medicaid pays / ea
$1.6681
gross reimbursed
vs
NADAC / ea
$1.7420
acquisition cost
=
Spread
−$0.0739
-4% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
44% FFS56% MCO
Fee-for-service · 1,064 Rx Managed care · 1,330 Rx
State Medicaid map
Units reimbursed · per 100k residents
21.9706
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
1West Virginia706 /100k
2Connecticut219 /100k
3Louisiana180 /100k
4Alabama157 /100k
5Kentucky148 /100k
6Massachusetts136 /100k
7Maine133 /100k
8Hawaii133 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
Medicaid utilization by pack size
Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
Drug total (last 4 qtrs): 2,771 Rx · 326,027 units · $551,433 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
Medicare Part D spend CMS · PART D · 2026 (Q1)
Medicare Part D (outpatient prescription) spending for Dilantin — the program that covers self-administered drugs. 2 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Dilantin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$6.06M
Claims incl. refills
24.1K
Beneficiaries
12.7K
Spend / beneficiary
$476.79
Spend / claim
$251.88
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for DILANTIN (this brand).
Top reported reactions
Convulsion2,156
Seizure1,426
Fall910
Drug Hypersensitivity852
Dizziness848
Headache829
Fatigue805
Age at onset
Neonate3
Infant7
Child14
Adolescent8
Adult427
Elderly229
Reporter sex
Male · 44%
Female · 56%
Unknown · 1%
Serious outcomes
Hospitalization5,211
Death1,191
Life-threatening542
Disabling498
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
Finished prescription productNo longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes)
✓ Available
Labeler
✓ Available
Product & package description
✓ Available
Marketing category & status
✓ Available
Active ingredient / dosage form / route
✓ Available
FDA label (SPL via DailyMed)
— Not published for this NDCNo structured label is linked to this listing in DailyMed/openFDA.
Package photos
— Not published for this NDCThe FDA label for this product carries no photos.
Inactive ingredients (structured)
— Not published for this NDCThe labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS)
✓ Available
Orange Book / therapeutic-equivalence data
— Not published for this NDCApplies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk
— Not published for this NDCMost self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD)
✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Why is there no full label on this page?
No structured FDA label (SPL) is currently linked to this NDC in DailyMed/openFDA. That can happen with older listings, certain OTC and repackaged products, and recently updated listings whose label has not yet propagated. The listing itself is still valid — this page shows everything the public feeds provide for this package.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Does this product come in other package sizes?
Yes — the FDA directory lists 2 other package presentations of this same product, including 100 capsules (00071-0369-40), 1000 capsules (00071-0369-32). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Parke-Davis Div of Pfizer Inc is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.